DecisionHealth, DecisionHealth - 2022 Issue 8 (August)

Part D plan preference for higher-cost hepatitis C drugs led to higher Medicare and beneficiary spending

On August 11, the OIG published a review of the utilization of hepatitis C drugs in Medicare Part D compared to utilization of the same drugs in Medicaid in 2019 and 2020. The review was conducted because preliminary research indicated that Part D beneficiaries were using higher-cost hepatitis C drugs rather than the generic versions that were increasingly being used by Medicaid beneficiaries.

To read the full article, sign in and subscribe to the DecisionHealth Newsletters.

Official DecisionHealth® Newsletter Archives includes:

  • Includes over 25,000 articles from:
    • Coder Pink Sheets
    • Part B News
    • Answer Books newsletters
  • Current newsletters added each quarter
  • Timely news and guidance vital for your practice
  • Fully searchable through Find-A-Code's Comprehensive Search
  • Codes mentioned in articles are linked to the Find-A-Code Code Information pages
  • Code Information pages link back to related articles
  • Save yourself tons of research time, find everything in one place!
Access to this feature is available in the following products:
  • DecisionHealth Coding, Billing and Compliance Library

demo
request yours today
 subscribe
start today
 newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.